Advaxis, Inc. (ADXS: OTCBB) is a biotechnology company that uses a bioengineered bacterium, Listeria monocytogenes to activate the immune system to treat cancer, infectious disease or allergic syndromes.
Of the many things that the immune system does, protecting us from pathologic bacterial infection is something that the immune system does the best. Our relationship with bacteria is complex, given that the average human has 10 trillion cells, yet is colonized by about 10 billion bacteria; most of which are helpful and necessary to good health. Because most of the time humans mount a very strong immune response to harmful bacteria, Advaxis has turned toward this effective response as a way to use the immune system to attack cancers. The company has found is a novel way to use the immune system with a higher level of therapeutic activity than is possible using other immune stimulatory approaches.
Based upon more than 20 years of discovery by Yvonne Paterson, Ph.D., Professor of Microbiology at the University of Pennsylvania, it has been found that this unique microbe is capable of stimulating numerous aspects of the immune system simultaneously; including, strongly stimulating innate immunity and both arms of the cellular adaptive immune response, stimulating non-classical immune mechanisms in the blood and bone marrow, and altering tumor microenvironments to allow the immune response to work.
This unique approach has resulted in extremely effective agents for the treatment of existing cancers and other diseases. Unlike other therapeutic approaches, in pre-clinical research Advaxis’ Listeria technology has been able to consistently demonstrate complete therapeutic responses resulting in complete tumor regression. Preliminary results in humans have shown this technology to be safe, and the therapeutic outcomes are very encouraging.
The company bioengineers live attenuated Listeria to secrete antigenic targets as an antigen-adjuvant fusion proteins. The company’s biotechnology uses a modified infectious microorganism to activate the immune system to treat cancer, infectious disease or allergic syndromes. It has been found that the unique microbe Listeria monocytogenes is capable of stimulating numerous aspects of the immune system simultaneously; including innate immunity, both arms of the adaptive immune response, as well as many non-classical immune responses in an extremely effective therapeutic response to existing cancers and other diseases.
Why Advaxis is different from other immunotherapies:
- It is the only commercial bacteria vector
- It utilizes a pre-existing immune reaction that is far more comprehensive than the reactions other approaches create and directs it to the tumor
- It reduces by 80% the regulatory T cells inside tumors that hinder immune attack
- It has shown consistent elimination of 70% of pre-existing tumors in preclinical testing among normal animals
- Once tumors have been cleared in these animals, they cannot be reintroduced.
- Initial human results demonstrate safe administration and encouraging early signs of efficacy
For more information, visit: http://www.advaxis.com/